In a report released today, Michael Matson from Needham reiterated a Buy rating on Haemonetics (HAE), with a price target of $122.00. The company’s shares closed last Wednesday at $98.25.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 8.5% and a 58.4% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Haemonetics with a $126.75 average price target, representing a 21.6% upside. In a report issued on October 22, Raymond James also initiated coverage with a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Haemonetics’ market cap is currently $5.18B and has a P/E ratio of 54.70. The company has a Price to Book ratio of 20.32.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HAE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.
